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i:10.1016/j.ejvs.2011.03.018In medicine, like politics, the ‘data’ or ‘facts’ can be
interpreted in more than one way. This interpretation or
‘spin’ is often more important than anything else. According
to the recent guidelines by the American Heart Association/
American Stroke Association (AHA/ASA) and several other
associations, “carotid artery stenting (CAS) is indicated as
an alternative to carotid endarterectomy (CEA) for symp-
tomatic patients at average or low risk of complications
associated with endovascular intervention when the diam-
eter of the lumen of the internal carotid artery is reduced by
more than 70% as documented by noninvasive imaging or
more than 50% as documented by catheter angiography and
the anticipated rate of periprocedural stroke or mortality is
less than 6% (Class I; Level of Evidence B)”.1 The recent
Carotid Revascularization Endarterectomy vs. Stenting Trial
(CREST) results were used to support this recommendation.2
However, the facts leading to this recommendation may
have more than one interpretation. This commentary
addresses another possible interpretation.
Carotid artery stenting: an alternative for
whom?
According to Webster’s New World Dictionary, ‘alternative’
is defined as “a choice between two things”.3 Thus, in the
AHA/ASA recommendation, the word ‘alternative’ may
easily be misinterpreted as ‘equivalent’ to justify the
widespread use of carotid artery stenting (CAS). Current
data, however, indicate that CAS should be viewed neithery for Vascular Surgery. Publisheas an ‘alternative’ nor as an ‘equivalent’ treatment option
to carotid endarterectptomy (CEA) in the majority of
symptomatic patients.
In CREST,2 there was no significant difference in the
estimated 4-year rates of the composite primary end point
between CAS and CEA (7.2% vs. 6.8%, respectively; relative
risk (RR) 1.11; 95% confidence interval (CI) 0.81e1.51;
p Z 0.51). The composite primary end point, however,
consisted of stroke, myocardial infarction (MI) or death
from any cause.2 Although CAS was associated with
considerably higher periprocedural stroke rates compared
with CEA (4.1% vs. 2.3%, respectively; hazard ratio (HR)
1.79; 95% CI 1.14e2.82; p Z 0.012), this was offset by
a reduced risk of MI (1.1% vs. 2.3%, respectively;
p Z 0.032).2 A recent subgroup analysis of CREST showed
that in symptomatic patients CAS was associated with an
almost twofold increase in periprocedural stroke and death
rates compared with CEA (6.0%  0.9% vs. 3.2%  0.7%,
respectively; HR 1.89; 95% CI 1.11e3.21; p Z 0.02).4
Therefore, CAS only showed equivalence of outcomes
with CEA when MIs were added to strokes. Quality-of-life
indices, however, show that both major and minor strokes
are likely to produce long-term physical limitations (with
minor stroke associated with worse mental and physical
health at 1 year), whereas the effect of periprocedural MI
on long-term physical and mental health is less.2,5
In addition to CREST, several other randomised studies
have demonstrated that in symptomatic patients CAS is
associated with higher rates of stroke,68 as well asd by Elsevier Ltd. All rights reserved.
Table 1 Randomized controlled trial (RCT) results showing higher rates of stroke/death and recurrent carotid stenosis after
CAS than CEA.
Study (year) Study design Study outcome
EVA-3S7
(2008)
4-year data of EVA-3S Incidence of 30-day stroke/death rate: 15 of the 262 vs. 29 of the 265
patients, or 6.2% vs. 11.1%, for CEA vs. CAS, respectively (HR 1.97; 95%
CI 1.06e3.67; p Z 0.03 for CAS vs. CEA).
SPACE9
(2008)
2-year data of SPACE Incidence of ‡70% recurrent carotid stenosis: 10.7% vs. 4.6%, for CAS vs.
CEA, respectively; p Z 0.0009; or 11.1% vs. 4.6%, for CAS vs. CEA,
respectively; p Z 0.0007, in the intention-to-treat and per-protocol
life-table estimates, respectively.
Steinbauer
et al. 8
(2009)
Single-center RCT comparing the
long-term results (66  14.2 vs..
64  12.1 months, respectively) of
CAS (n Z 43) with CEA (n Z 44)
Patients undergoing CAS had higher rates of ipsilateral stroke
(4 of 42 vs. 0 of 42 patients, respectively; p < 0.05) and >70% recurrent
carotid stenosis (6 of 32 vs. 0 of 29, respectively; p < 0.05) compared
with patients undergoing CEA.
ICSS6
(2010)
120-day data from
1710 symptomatic patients
randomized to CAS vs. CEA
Patients undergoing CAS (n Z 828) had a higher (vs.. CEA, n Z 821) risk
of any stroke (65 vs. 35 events, or 7.7% vs. 4.1%, respectively; HR 1.92;
95% CI 1.27e2.89; p Z 0.002), any stroke or death (72 vs. 40 events, or
8.5% vs. 4.7%, respectively; HR 1.86; 95% CI 1.26e2.74; p Z 0.0001),
all-cause death (19 vs. 7 events, or 2.3% vs. 0.8%, respectively; HR 2.76;
95% CI 1.16e6.56; p Z 0.017).
CREST4
(2011)
RCT of 2502 (1181 asymptomatic;
1321 symptomatic) patients to CEA
(n Z 1240) or CAS (n Z 1262)
Symptomatic patients undergoing CAS had a higher incidence of any
periprocedural stroke (37 vs.. 21 events, or 5.5%  0.9% vs. 3.2%  0.7%,
respectively; HR 1.74; 95% CI 1.02e2.98; p Z 0.04) and a higher incidence
of any periprocedural stroke or death (40 vs. 21 events or 6.0%  0.9% vs.
3.2%  0.7%, respectively; HR 1.89; 95% CI 1.11e3.21; p Z 0.02)
compared with patients undergoing CEA.
EVA-3S10
(2011)
2-year carotid ultrasound follow-up
data for 242 CAS patients and 265
CEA patients of EVA-3S
The rate of carotid restenosis of 50% or occlusion was higher after CAS
than after CEA (12.5% vs. 5.0%, respectively; time ratio 0.16; 95%
CI 0.03e0.76; p Z 0.02).
EVA-3S: Endarterectomy vs. Angioplasty in patients with Symptomatic Severe Carotid Stenosis; CEA: carotid endarterectomy; CAS: carotid
artery stenting; HR: hazard ratio; CI: confidence interval; SPACE: Stent-Protected Angioplasty vs. Carotid Endarterectomy; RCT: randomized
controlled trial; ICSS: International Carotid Stenting Study; CREST: Carotid Revascularization Endarterectomy vs. Stenting Trial.
718 Editorialrecurrent carotid stenosis rates810 (Table 1). CAS is also
considerably more expensive than CEA.11 In addition,
several recent meta-analyses have concluded that CAS is
associated with inferior outcomes compared with CEA.1215
According to one meta-analysis (n Z 13 trials; 7484
patients; 80% symptomatic),12 CAS is associated with an
increased risk of any stroke compared with CEA (RR 1.45;
95% CI 1.06e1.99; I2 Z 40%). The conclusion reached was
that “for every 1000 patients opting for CAS rather than
CEA, 19 more patients would have strokes”.12 These results
were verified in another independent meta-analysis.13 Both
meta-analyses, however, concluded that the superiority of
CEA over CAS disappeared in patients <70 years. According
to a recent large registry (n Z 47 752 CAS and CEA hospi-
talisations matched by propensity score), the most appro-
priate procedure in symptomatic patients with carotid
artery stenosis is CEA, whereas CAS appears to be a suitable
minimally invasive approach for asymptomatic patients.16
According to the recent inter-collegiate Australasian CAS
guidelines, “CASmaybe considered as a treatment option for
patientswith symptomatic severe carotid stenosiswhoare at
high risk of stroke, but are surgically unsuitable for CEA”.17
This includes specific patient subgroups and conditions,
namely (1) post-radiation therapy, (2) block dissection of the
neck, (3) in situ tracheostomy, (4) recurrent stenosis
following previous CEA, (5) severe cervical spine arthritis, (6)
surgically inaccessible carotid stenosis (e.g., obesity andhigh carotid bifurcation), (7) contralateral recurrent laryn-
geal nerve injury and (8) contralateral internal carotid artery
occlusion.17 Apart from these conditions, CAS should not be
considered as an alternative to CEA for the management of
symptomatic carotid stenosis except in patients <70 years
and those participating in randomised trials.17
Based on the results of meta-analyses,1215 randomised
controlled trials610 and population-based studies,11,16 CAS
may be an ‘alternative treatment’ but is clearly inferior to
CEA in the majority of symptomatic patients.17 Unstable
symptomatic carotid plaques are associated with an
increased incidence of new ipsilateral silent embolic events
after CAS compared with CEA.1820 In the absence of data
showing comparable risks of stroke and silent emboli for
CAS, angioplasty and stenting should only be offered to
symptomatic patients when mitigating factors suggest an
unacceptable risk with CEA.
It is likely that CAS will continue to improve with (1)
better patient selection, (2) better embolic protection
devices, (3) better stents (membrane or mesh covered), (4)
technical improvements (e.g., avoiding aortic arch manip-
ulations) and (5) additional operator experience.19 Adop-
tion of all these may well improve CAS outcomes and make
it a fair alternative to CEA, at least in certain patient
subgroups. However, the current evidence indicates that
we are not there yet, and it seems unfair to spin either
CREST2 or the AHA/ASA guidelines1 to conclude that we are.
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